Aaron Kesselheim, MD, JD, MPH, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research center that focuses on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, and has been asked to serve on select advisory committees for the FDA and National Academies of Science, Engineering, and Medicine. Aaron also serves as a Visiting Associate Professor of Law at Yale Law School, where he teaches a yearly course on Food and Drug Administration Law, and as a faculty member at the Harvard Medical School Center for Bioethics. He is the author of over 250 articles in the peer-reviewed medical and health policy literature and serves as Editor-in-Chief of the Journal of Law, Medicine, and Ethics.
Clip by Amitabh Chandra & Aaron S. Kesselheim
What impact do market exclusivity periods have on the cost of drugs and on incentives for innovation?
Clip by Michael S. Sherman, Aaron S. Kesselheim & Amitabh Chandra
Is it always a multiple of years of life saved? And is value-based contracting a reasonable approach to reining in prices?
Article by Michael Fralick, Jerry Avorn & Aaron S. Kesselheim
The health and safety risks faced by the many Americans who cannot afford medications necessitate consideration of alternative strategies to provide less expensive medications.
A payer describes the barriers in moving toward value-based drug pricing.
Article by Ameet Sarpatwari, Jerry Avorn & Aaron S. Kesselheim
Spending on prescription drugs has shot up. Ten states are debating transparency laws to require pharmaceutical companies to disclose research and development costs. Here’s why that effort is unlikely to work.